Latest ArticlesTo explore the mechanism of kaempferol on adriamycin resistance sensitivity of lung cancer cells based on transforming growth factor β1/Ras related C3 botox substrate 1 (TGF-β1/Rac1) signaling pathway.
H1299/R cells were divided into negative control group (NC), kaempferol low, medium and high-dose groups, TGF-β1 inhibitor group, Rac1 inhibitor group, kaempferol high-dose+TGF-β1 inhibitor group, kaempferol high-dose+Rac1 inhibitor group, and kaempferol high-dose+TGF-β1 inhibitor+Rac1 inhibitor group. MTT assay was used to detect the cell growth inhibition rate and drug resistance sensitivity. Flow cytometry was used to detect the cell apoptosis. Transwell chamber was used to detect the cell invasion. Western blotting was used to detect the expression of TGF-β1 and Rac1 protein.
Compared with NC group, the half inhibitory concentration (IC50), cell invasion ability in kaempferol low, medium and high-dose groups, TGF-β1 inhibitor group, Rac1 inhibitor group were significantly decreased, while the cell apoptosis rate was increased, and the expression of TGF-β1 and Rac1 protein were significantly decreased (P<0.05). Compared with the kaempferol high-dose group, the IC50, cell invasion ability, TGF-β1 and Rac1 protein expression of H1299/R cells in kaempferol high-dose+TGF-β1 inhibitor group, kaempferol high-dose+Rac1 inhibitor group, and kaempferol high-dose+TGF-β1 inhibitor+Rac1 inhibitor group were significantly decreased, while the cell apoptosis rate was significantly increased (P<0.05).
Kaempferol can reverse adriamycin resistance in lung cancer cells, inhibit the invasion of adriamycin resistant cells and promote apoptosis, the mechanism may be related to the inhibition of TGF-β1/Rac1 signaling pathway.
To investigate the inhibitory effect of β-sitosterol on quercetin in A549 cells and its mechanism.
The A549 cells were divided into control group, quercetin group, quercetin+β-sitosterol group, estradiol group, estradiol+quercetin group, and estradiol+quercetin+β-sitosterol group. The cell survival rate the inhibitory effects of A549 cell. The flow cytometry and immunofluorescence methods were used to determine the pro-apoptotic effect of on lung cancer cells. Western blotting was used to the regulatory effects of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway.
Quercetin could inhibit the survival rate of A549 cells with dose-response relationship (P<0.05). Estradiol promoted the growth of A549 cells. Compared with quercetin group or quercetin+β-sitosterol group, estradiol+quercetin+β-sitosterol group more inhibited the proliferation of A549 cells, increased the proportion of apoptosis and the expression level of caspase-3 (P<0.05), promoted the phosphorylation of mTOR and AKT, and decreased the phosphorylation of PI3K.
Under the intervention of estradiol, β-sitosterol combined with quercetin inhibited A549 cells, the mechanism of which may be through the PI3K/Akt/mTOR pathway of apoptosis.
To investigate the effects of ophiopogonin B on epithelial mesenchymal transformation (EMT), chemotherapy resistance and sonic hedgehog (Shh)/glioma associated oncogene homolog (Gli)1 pathway in hepatocellular carcinoma.
Screening suitable concentration of ophiopogonin B. The HepG2 cells were divided into control group, ophiopogonin B low (group A), medium (group B), high concentration group (group C) and ophiopogonin B high concentration+Shh agonist group (group D). The HepG2/adriamycin (ADM) cells were divided into HepG2/ADM group, ADM group, ophiopogonin B group and ADM+ophiopogonin B group. HepG2 cell proliferation, apoptosis, EMT, Shh/Gli1 pathways and related protein expression were detected. HepG2/ADM cells were treated to detect cell proliferation, apoptosis, Shh and Gli1 proteins.
Compared with the control group, 5-ethynyl-2'-deoxyuridine (EdU) positive rate, the expressions of Ki67, B cell lymphoma (Bcl)-2, neural cadherin, vimentin, Shh and Gli1 in groups A, B and C decreased successively, while the apoptosis rate, Bcl-2 associated X protein (Bax) and cadherin expression in epithelial cells increased successively (P<0.05). Compared with group C, Edu positive rate, Ki67, Bcl-2, neural cadherin, vimentin, Shh and Gli1 expressions in group D were increased, while apoptosis rate, Bax and cadherin expression in epithelial cells were decreased (P<0.05). Compared with HepG2/ADM group, EdU positive rate, Shh and Gli1 expressions in ADM and ophiopogonin B group decreased, and apoptosis rate increased (P<0.05). Compared with ADM and ophiopogonin B groups, Edu positive rate, Shh and Gli1 expressions were decreased in ADM+ophiopogonin B group, and apoptosis rate was increased (P<0.05).
Ophiopogonin B inhibits EMT of HepG2 cells by inhibiting Shh/Gli1 pathway and reducing chemotherapy resistance.
To investigate the effects of stanozolol combined with conventional therapy on predicting adult height (PAH) and gonadal development in children with idiopathic central precocious puberty (ICPP).
A total of 80 ICPP children admitted to our hospital from June 2018 to June 2020 were randomly divided into control group (routine regimen) and observation group (routine regimen+stanozolol), with 40 cases in each group. The results of PAH and gonad development in the two groups were compared.
After treatment, the growth rate and PAH in observation group were higher than those in control group (P<0.05). Tanner stage and pubic hair stage were better than control group (P<0.05). The volume of left and right ovary was lower than that of control group (P<0.05). In the observation group, the effect of children with large bone age (11 - 14 years old) to achieve PAH was better than that of children with small bone age (8 - 11 years old) (P<0.05). No serious drug-related adverse reactions occurred in the two groups during treatment.
Stanozolol is effective in the treatment of ICPP in children, can significantly improve the prediction of PAH, improve symptoms, inhibit gonadal development, and has good safety, especially for growth promotion in children with large bone age.
To analyze the effects of self-designed Qufeng Yangxue Runfu liquid bath combined with levocetirizine hydrochloride on itchy scratching behavior and calcium and phosphorus metabolism in patients with maintenance hemodialysis (MHD).
A total of 80 patients with regular MHD and blood vacuity and wind-driness in our hospital from January 2021 to August 2022 were selected and divided into control group (conventional treatment+levocetirizine hydrochloride) and observation group (conventional treatment+levocetirizine hydrochloride+self-designed Qufeng Yangxue Runfu liquid bath) by random number table method, with 40 cases in each group. Pruritus score, blood calcium, blood phosphorus, parathyroid hormone (PTH), hypersensitive C-reactive protein (hs-CRP), interleukin (IL)-6 and clinical efficacy were compared between the two groups before and after treatment.
After treatment, the levels of pruritus score, blood phosphorus, PTH, hs-CRP and IL-6 in both groups were decreased (P<0.05), and the observation group was lower than the control group (P<0.05). The serum calcium level in both groups were higher than before (P<0.05), and the observation group was higher than the control group (P<0.05). The curative effect of observation group was significantly higher than that of control group (87.50% vs 67.50%, P<0.05).
Self-designed Qufeng Yangxue Runfu liquid bath combined with levocetirizine hydrochloride has a better effect on skin pruritus in MHD patients, which can effectively relieve pruritus, improve calcium and phosphorus metabolism, and reduce inflammation in vivo.
To analyze the effects of Qinxitong tablets combined with tripterygium glycosides on platelet aggregation and B cell expression in patients with rheumatoid arthritis (RA).
A total of 100 RA patients admitted to our hospital from January 2021 to February 2022 were selected and divided into study group (tripterygium glycosides+methotrexate+Qinxitong tablets, n=49) and control group (tripterygium glycosides+methotrexate, n=51) according to simple sorting random method. The efficacy, clinical symptom score, helper T cell (Th)17/regulatory T cell (Treg) and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), cyclic citrullinated peptide (CCP), soluble growth stimulation expressed gene 2 protein (sST2), matrix metalloproteinases (MMP)3, rheumatoid factor (RF), human platelet α granule membrane glycoprotein (CD62p), CD41, chemokine C-X-C motif ligand (CXCL)13 and the incidence of complications were compared between the two groups.
After treatment, the total effective rate of the study group was higher than that of the control group (95.92% vs 74.51%, P<0.05). The scores of morning stiffness, joint pain, joint swelling and joint tenderness were lower than those of control group (P<0.05). The levels of Th17/Treg, CRP and ESR were lower than those of control group (P<0.05). The levels of sST2, MMP3 and RF were lower than those of control group (P<0.05). Serum levels of CD62p and CD41 were lower than those of control group (P<0.05). The level of CXCL13 was lower than that of control group (P<0.05). The total complication rate was lower than that of control group (P<0.05).
Qinxitong tablets combined with tripterygium glycosides can effectively relieve the clinical symptoms of RA patients, inhibit platelet aggregation, reduce the expression of inflammatory cells and B cell, and control the levels of sST2, MMP3 and RF, which is safe and effective.
To perform a rapid health technology assessment (rHTA) on the safety, effectiveness, and economy of pertuzumab in human epidermal growth factor receptor (HER)2-positive breast cancer, and to provide an evidence-based basis for clinical drug decision.
Pubmed, Cochrane Library, Embase, CNKI, Wanfang, official HTA websites were systematically searched. References were screened according to the inclusion and exclusion criterion. And the results were analyzed by data extraction and quality evaluation.
20 systematic review/meta-analysis, 12 economic studies and 4 HTA were included in our study. The results of the study showed that in terms of effectiveness, pertuzumab can improve the pathologic conplete remission (pCR) and objective remission rate (ORR) of trastuzumab, pCR and disease free survival (DFS) of trastuzumab plus chemotherapy for neoadjuvant breast cancer patients. For the patients with metastatic breast cancer, pertuzumab can improve the progression-free survival (PFS) of trastuzumab, PFS, ORR, 1-year, 2-year and median overall survival (OS) of trastuzumab plus taxol, the OS of trastuzumab plus capecitabine. In terms of safety, pertuzumab had mild side effects and good safety. In terms of economy, the combination of pertuzumab was not economical both in abroad and at home.
Pertuzumab was effective and safe in the treatment of HER2-positive breast cancer, but the economy was poor.
To evaluate the safety, efficacy and economy of lorlatinib as the first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by rapid health technology assessment (rHTA), and to provide evidence for clinical decision makers.
Domestic and foreign databases and other major official HTA websites were used, and the related literatures about lorlatinib as first-line treatment for ALK mutation-positive NSCLC patients were included and comprehensively analyzed.
A total of 9 systematic/meta-analyses and 4 economic studies were included. Efficacy results showed that objective response rate and progression-free survival of lorlatinib were significantly better than other ALK-tyrosine kinase inhibitors and chemicals, but overall survival was not significantly different. Safety results showed that the incidence of adverse events of lorlatinib≥3 was only lower than ceritinib, but controllable. Economic results did not show a significant cost-effectiveness advantage.
Lorlatinib has efficacy and safety advantages in the first-line treatment of ALK mutation-positive NSCLC patients, but its economic advantages need to be further studied. More safety, effectiveness and economic studies focusing on intuitive comparison and multi-subgroup are necessary.
Ceftazidime/avibactam is a combination of third-generation ceftazidime and novel non-beta-lactamase inhibitors. At present, it has been approved for the clinical treatment of severe infections with limited therapeutic drugs such as hospital-acquired pneumonia, ventilator-associated pneumonia, and complex abdominal infection, and it also has been gradually applied in the clinical treatment of complex urinary tract infection and intracranial infection, and has shown obvious advantages. This article summarized the pharmacological action, pharmacokinetics, clinical application and drug use methods of ceftazidime/avibactam, in order to provide some reference for clinical drug selection and promote rational drug use.